secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001447362-22-000135
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Q2 revenue $34.8M (+53%); raises 2022 guidance to $130-135M
------------------------------------------------------------------

- Q2 total test reports 11,034 (+57% YoY); skin cancer GEP volume up 44% YoY.
- Net loss $(1.6)M improved from $(8.8)M; adjusted EBITDA $(10.9)M vs $(3.4)M.
- 2022 revenue guidance raised to $130-135M from $118-123M; cash $273M.
- DecisionDx-Melanoma test linked to 27% improvement in melanoma-specific survival in NCI collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736222000135/0001447362-22-000135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736222000135/cstl-20220808.htm
  HTML page:      https://secwatch.observer/filing/0001447362-22-000135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer